Celdoxome pegylated liposomal is a medicine used to treat the following types of cancer in adults: - metastatic breast cancer in patients at risk of heart problems. ‘Metastatic’ means the cancer has spread to other parts of the body. Celdoxome pegylated liposomal is used on its own for this disease; - advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working; - Kaposi’s sarcoma in patients with AIDS who have very damaged immune system. Kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs; - multiple myeloma (a cancer of the cells in the bone marrow), in patients with progressive disease who have received at least one previous treatment and have already had a bone marrow transplantation or are unsuitable for it. Celdoxome pegylated liposomal is used in combination with bortezomib (another cancer medicine). Celdoxome pegylated liposomal contains the active substance doxorubicin. Celdoxome pegylated liposomal is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance, but in Celdoxome pegylated liposomal the active substance is enclosed in ‘pegylated liposomes’ (tiny fat particles coated with a substance called polyethylene glycol) while this is not the case for the reference medicine. The reference medicine for Celdoxome pegylated liposomal is Adriamycin.
Therapeutic Indication
### Therapeutic indication Celdoxome pegylated liposomal is indicated in adults: - as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. - or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. - in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. - for treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts (< 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. Celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
Therapeutic Area (MeSH)
ATC Code
L01DB01
ATC Item
doxorubicin
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| doxorubicin hydrochloride | N/A | 多柔比星 |
EMA Name
Celdoxome pegylated liposomal
Medicine Name
Celdoxome pegylated liposomal
Aliases
N/ANo risk management plan link.
